FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1796-1797 June 7, 2001 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The editorial by Sapirstein et al. (Jan. 25 issue)¹ on the study by Leon et al.² of intracoronary gamma-radiation therapy to prevent restenosis speaks of the desire of the Food and Drug Administration (FDA) to navigate "a course between the Scylla of unacceptable risk and the Charybdis of inadequate effectiveness" and to address "the need for an effective intervention in a serious clinical situation." In approving these devices the FDA required special warnings concerning their use as well as a post-marketing study that included a five-year follow-up of treated patients. Despite the caution called for by Sheppard . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Shuhaiber, J. H., Evans, A. N., Massad, M. G., Geha, A. S. (2002). Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur. J. Cardiothorac. Surg. 22: 387-396 [Abstract] [Full Text]